Toxins and drug discovery
Harvey, Alan L. (2014) Toxins and drug discovery. Toxicon, 92. pp. 193-200. ISSN 1879-3150
![]()
|
PDF (Harvey-Toxicon-2014-Toxins-and-drug-discovery)
Harvey_Toxicon_2014_Toxins_and_drug_discovery.pdf Final Published Version License: ![]() Download (397kB)| Preview |
Abstract
Components from venoms have stimulated many drug discovery projects, with some notable successes. These are briefly reviewed, from captopril to ziconotide. However, there have been many more disappointments on the road from toxin discovery to approval of a new medicine. Drug discovery and development is an inherently risky business, and the main causes of failure during development programmes are outlined in order to highlight steps that might be taken to increase the chances of success with toxin-based drug discovery. These include having a clear focus on unmet therapeutic needs, concentrating on targets that are well-validated in terms of their relevance to the disease in question, making use of phenotypic screening rather than molecular-based assays, and working with development partners with the resources required for the long and expensive development process.
Creators(s): | Harvey, Alan L.; | Item type: | Article |
---|---|
ID code: | 51797 |
Keywords: | conus venoms, drug development venoms to drugs, drug discovery, phenotypic screening, snake venoms, Pharmacy and materia medica, Toxicology |
Subjects: | Medicine > Pharmacy and materia medica |
Department: | University of Strathclyde > University of Strathclyde Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Faculty of Science |
Depositing user: | Pure Administrator |
Date deposited: | 19 Feb 2015 14:47 |
Last modified: | 17 Jan 2021 02:52 |
Related URLs: | |
URI: | https://strathprints.strath.ac.uk/id/eprint/51797 |
Export data: |